Pherecydes Pharma: Funding, Investors & Team (Sep 2026)
Pherecydes Pharma operator of an innovative biotechnologies company created to develop personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and launched multicenter European phage therapy trial to evaluate phage therapy on infected burn wounds, recognize bacterial target attached to its outer membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria.
Pherecydes Pharma has raised $2.3M across 1 funding round on record, the most recent a Grant of $2.3M announced in Jan 2022.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Pherecydes Pharma Company Profile and Key Stats
Latest funding round on record: Jan 2022.
Pherecydes Pharma Funding Rounds
Pherecydes Pharma Founders and Leadership Team
No contact details are on record for this team yet.
Pherecydes Pharma Funding Compared to Other Biotechnology Startups
Pherecydes Pharma's latest round of $2.3M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Pherecydes Pharma in Biotechnology and Romainville
Companies Similar to Pherecydes Pharma
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
Pherecydes Pharma Funding FAQs
What does Pherecydes Pharma do?
Pherecydes Pharma operator of an innovative biotechnologies company created to develop personalized phage therapy to treat bacterial infections. The company develops bacteriophages against infections and launched multicenter European phage therapy trial to evaluate phage therapy on infected burn wounds, recognize bacterial target attached to its outer membrane, inject genetic material and reproduce in the host to make new phages that get out and repeat the same cycle, enabling doctors to detect and treat people and their environment against a large range of biothreat agents, including multi-resistant, emergent or previously uncharacterized bacteria.
How much funding has Pherecydes Pharma raised?
Pherecydes Pharma has raised $2.3M across 1 round on record. The most recent is a Grant of $2.3M announced in Jan 2022.
When did Pherecydes Pharma last raise funding?
Pherecydes Pharma's most recent funding round on record is a Grant of $2.3M, announced in Jan 2022.
Who is the CEO of Pherecydes Pharma?
Guy Charles Fanneau de La Horie is listed as CEO at Pherecydes Pharma.
Where is Pherecydes Pharma headquartered?
Pherecydes Pharma is based in Romainville, Ile-De-France, France.
How many employees does Pherecydes Pharma have?
Pherecydes Pharma is in the 11-50 employee band.
How does Pherecydes Pharma's funding compare to other Biotechnology startups?
Pherecydes Pharma's latest round of $2.3M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Pherecydes Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Pherecydes Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.